Ligand-independent signaling by disulfide-crosslinked dimers of the p75 neurotrophin receptor
Dimerization is recognized as a crucial step in the activation of many plasma membrane receptors. However, a growing number of receptors pre-exist as dimers in the absence of ligand, indicating that, although necessary, dimerization is not always sufficient for signaling. The p75 neurotrophin recept...
Saved in:
Published in | Journal of cell science Vol. 122; no. 18; pp. 3351 - 3357 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
The Company of Biologists Limited
15.09.2009
Company of Biologists |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Dimerization is recognized as a crucial step in the activation of many plasma membrane receptors. However, a growing number of receptors pre-exist as dimers in the absence of ligand, indicating that, although necessary, dimerization is not always sufficient for signaling. The p75 neurotrophin receptor (p75NTR) forms disulfide-linked dimers at the cell surface independently of ligand binding through Cys257 in its transmembrane domain. Here, we show that crosslinking of p75NTR dimers by cysteine-scanning mutagenesis results in constitutive, ligand-independent activity in several pathways that are normally engaged upon neurotrophin stimulation of native receptors. The activity profiles of different disulfide-crosslinked p75NTR mutants were similar but not identical, suggesting that different configurations of p75NTR dimers might be endowed with different functions. Interestingly, crosslinked p75NTR mutants did not mimic the effects of the myelin inhibitors Nogo or MAG, suggesting the existence of ligand-specific activation mechanisms. Together, these results support a conformational model of p75NTR activation by neurotrophins, and reveal a genetic approach to generate gain-of-function receptor variants with distinct functional profiles. |
---|---|
Bibliography: | Author for correspondence (carlos.ibanez@ki.se) Present address: Department of Pharmacology, Faculty of Medicine, University of Crete, Greece (I.C.), and Service of Neurology, Research Center, Hospital 12 de Octubre, Madrid, Spain We thank Masami Kojima and Phyllis Dan for purified proBDNF, Phil Barker for MC192 antibody, and Moses Chao (Skirball Institute, New York, NY), Toshihide Yamashita (Osaka University, Osaka, Japan), Anders Nykjær (Aarhus University, Aarhus, Denmark) and Daniel Lee (Biogen, Boston, MA) for RIP2, RhoGDI, sortilin and Lingo-1 expression plasmids. This work was supported by grants from the Swedish Foundation for Strategic Research, the Swedish Research Council (33X-10908-10A and Linné program), the Vth Framework Program of the European Union (QLG3-CT-1999-00573), and the National Institutes of Health (1 R01 MH071624-01A2). R.S.K. and B.D.C. were supported by the National Institutes of Health (R01 NS038220), A.R. and G.S. by Cancer Research UK. Deposited in PMC for release after 12 months. Present address: Centro Nacional de Investigaciones Oncologicas, Madrid, Spain |
ISSN: | 0021-9533 1477-9137 1477-9137 |
DOI: | 10.1242/jcs.055061 |